SI-BONE expects packaging-related recall work to affect approximately 3,900 implants and to generate an aggregate gross charge of up to approximately $150,000. Investors are told third-quarter Revenue is not otherwise expected to be affected, while the company says additional inventory should support implant Supply and physician treatment.
Key Highlights
- The company extended its Santa Clara headquarters Lease for a month at $43,696 in monthly base rent.
- A packaging failure prompted quarantine, repackaging and re-sterilization work involving affected iFuse TORQ inventory.
- SI-BONE recalled iFuse TORQ implants after tube packaging from specific lots failed sterile-barrier acceptance criteria, creating a potential infection risk.
- The company said third-quarter revenue is not otherwise expected to be affected, while additional on-hand inventory should support implant availability.
The company says third-quarter revenue is not otherwise expected to be affected, while additional on-hand inventory should support implant availability for physicians and patient treatment.
iFuse TORQ Packaging Issue Drives Recall Costs
The recall began after tube packaging from specific lots failed acceptance criteria for maintaining a sterile barrier, creating a potential infection risk. SI-BONE (NASDAQ: SIBN) said the affected inventory includes implants distributed to its field salesforce and customers, alongside units held in its Warehouse or managed by its implant manufacturer. The company and its Manufacturing partners are investigating the issue with the FDA. Costs include recalling and sorting warehouse inventory, then repackaging and re-sterilizing affected implants.
Santa Clara Lease Extended at $43,696 Monthly
SI-BONE also extended the lease covering approximately 21,848 square feet at its Santa Clara headquarters for a month. Base rent during that period is $43,696 per month, calculated at $2.00 per rentable square foot, while the company continues paying its share of operating expenses and taxes. The lease’s security deposit is $199,570.56. SI-BONE plans to seek recovery from the tube manufacturer, although the company said recovery is not assured. It expects to provide any further potential financial-impact details when reporting third-quarter results.
FAQs
Q: Will the SI-BONE recall affect revenue?
A: SI-BONE says third-quarter revenue is not otherwise expected to be affected by the recall or related activities. The company also expects implant supply to continue.
Q: What is the SI-BONE headquarters lease cost?
A: SI-BONE’s extended Santa Clara headquarters lease carries monthly base rent of $43,696 for approximately 21,848 square feet, with operating expenses and taxes payable separately.
Q: Is SI-BONE expecting the recall to affect third-quarter revenue?
A: SI-BONE said third-quarter revenue is not otherwise expected to be affected by the recall. Additional on-hand inventory should support implant availability for physicians and patient treatment.
Q: What caused the iFuse TORQ recall?
A: The recall covers implants from specific lots whose tube packaging failed acceptance criteria for maintaining a sterile barrier. A potential infection risk prompted the recall, involving units held across distribution channels.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.